Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. Pfizer ( PFE) ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This Elote en Vaso features flavorful tender corn in a cup served along with cream, cheese, hot sauce, and lime juice. The ...

(Reuters) -U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all ...

An inherited blood disorder, sickle cell disease can be managed with several treatment options to reduce painful episodes and ...

PLAINVIEW, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- (“Vaso”) (OTCQX: VASO) today announced that it has provided notice to Achari Ventures Holdings Corp. I (“Achari”) to terminate the Business ...

Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...

Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment ...

Researchers found that lactated Ringer (LR) solution may indeed surpass normal saline (NS) in helping the sickle cell disease ...

Pfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an ...

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

Vaso Corporation (“Vaso”) (OTCQX: VASO) today announced that it has provided notice to Achari Ventures Holdings Corp. I (“Achari”) to terminate the ...